Astrantus’s DexCom DXCM Stock Holding History

Astrantus’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8,800	Closed	-$1.18M	–	210
2021 Q4	$1.18M	Buy	+8,800	New	+$1.26M	0.88%	26

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Astrantus's DXCM Position: Q1 2022 in Review

Astrantus sold out of DexCom (DXCM) in Q1 2022, closing a stake of 8,800 shares — an estimated $1.18M sold.

Astrantus first reported a position in DXCM in Q4 2021 and held it in 1 quarter. The position peaked at $1.18M in Q4 2021. 862 funds tracked by Wall St. Rank hold DXCM as of Q1 2022.

Astrantus reported no remaining DexCom position as of Q1 2022 after selling out during the quarter.
Astrantus sold 8,800 DexCom shares in Q1 2022, an estimated $1.18M.
Astrantus first reported a position in DexCom in Q4 2021 and held it in 1 quarter.
Astrantus's DexCom position peaked at $1.18M in Q4 2021.
862 funds tracked by Wall St. Rank held DexCom as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.